Abstracts tagged "animal models and tumor necrosis factor (TNF)"

Abstract Number: 1770 • 2019 ACR/ARP Annual Meeting
Experimental Rheumatoid Joint Ameliorated by CRISPR Interference Targeting Long Non-coding RNA H19 Through Wnt Signaling Inactivation
Chrong-Reen Wang¹, Shih-Yao Chen ¹, Yu-Chi Chou ², Chao-Liang Wu ³, Yu-Ting Lo ¹ and Ai-Li Shiau ⁴, ¹National Cheng Kung University Hospital, Tainan, Taiwan (Republic of China), ²Genomics Research Center, Academia Sinica, Taipei, Taiwan (Republic of China), ³National Cheng Kung University Medical College, Tainan, Taiwan (Republic of China), ⁴National Cheng Kung University Medical College, Tainan, Taiwan (Republic of China)
Background/Purpose: Long non-coding RNAs (lncRNAs) participate in the rheumatoid arthritis (RA) pathogenesis. The aim of this study was to examine the lncRNA H19 and HOTAIR…
Abstract Number: 43 • 2018 ACR/ARHP Annual Meeting
Novel Anti-Malarial Drug Derivative Inhibited Anti-Citrullinated Protein/Peptide Antibodies and Rheumatoid Factors Production in Dnaseii/Ifnr Double Knock out Mice
Jie An¹, Bhanupriya Madarampalli², Xizhang Sun², Lena Tanaka³, Erika H. Noss², Joshua Woodward⁴, Tomikazu Sasaki⁵ and Keith B. Elkon⁶, ¹Division of Rheumatology, University of Washington, Seattle, WA, ²Rheumatology, University of Washington, Seattle, WA, ³Medicine/Rheumatology, University of Washington, Seattle, WA, ⁴Department of Microbiology, University of Washington, Seattle, WA, ⁵Department of Chemistry, University of Washington, Seattle, WA, ⁶University of Washington, Seattle, WA
Background/Purpose: Rheumatoid Arthritis (RA) is a highly prevalent autoimmune disease affecting ~1% of the world population and can lead to permanent joint damage and severe…
Abstract Number: 3148 • 2016 ACR/ARHP Annual Meeting
Peptidylarginine Deiminase 2 Is Required for Tumor Necrosis Factor Alpha Induced Citrullination and Arthritis, but Not Neutrophil Extracellular Trap Formation
Mandar Bawadekar¹, Daeun Shim¹, Ryan Rebernick¹, Chloe Peyton¹, Chad J. Johnson², Thomas F. Warner³, Dres Damgaard⁴, Claus Henrik Nielsen⁵, Anthony P. Nicholas⁶, Ger JM Pruijn⁷, Jeniel E. Nett⁸ and Miriam A. Shelef^1,9, ¹Department of Medicine, Division of Rheumatology, University of Wisconsin-Madison, Madison, WI, ²Department of Medicine, University of Wisconsin-Madison, Madison, WI, ³Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI, ⁴Institute for Inflammation Research, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, ⁵Danish Rheumatologic Biobank and DANBIO registry, Rigshospitalet, Glostrup, Gentofte and Herlev University Hospital, Copenhagen, Denmark, ⁶Neurology, University of Alabama at Birmingham and Birmingham VA Medical Center, Birmingham, AL, ⁷Biomolecular Chemistry, Institute for Molecules and Materials and Radboud Institute for Molecular Life Sciences, Radboud University, Nijmegen, Netherlands, ⁸Medicine and Medical Microbiology and Immunology, University of Wisconsin-Madison, Madison, WI, ⁹William S. Middleton Memorial Veterans Hospital, Madison, WI
Background/Purpose: The presence of anti-citrullinated protein antibodies in rheumatoid arthritis points to a potential role for citrullination in disease pathogenesis. Peptidylarginine deiminases (PADs) catalyze the…
Abstract Number: 1038 • 2015 ACR/ARHP Annual Meeting
Tumor Necrosis Factor Alpha and Peptidylarginine Deiminase 4 in Lung and Joint Inflammation
Mandar Bawadekar¹, Annette Gendron-Fitzpatrick², Thomas F. Warner³, Lennart K.A. Lundblad⁴, Paul Thompson⁵ and Miriam A. Shelef^1,6, ¹Medicine, University of Wisconsin, Madison, WI, ²Comparative Pathology Laboratory of the Research Animal Resources Center and Pathobiological Sciences, University of Wisconsin, Madison, WI, ³Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, WI, ⁴Medicine, The University of Vermont, Burlington, VT, ⁵University of Massachusetts, Worcester, MA, ⁶Medicine, William S. Middleton Memorial Veterans Hospital, Madison, WI
Background/Purpose: The relationship between lung and joint inflammation in rheumatoid arthritis is poorly understood. About 10% of people with rheumatoid arthritis develop interstitial lung disease…
Abstract Number: 2582 • 2015 ACR/ARHP Annual Meeting
Increased Morbidity and Mortality in Female Versus Male Tumor Necrosis Factor-Transgenic Mice
Richard Bell¹, Ronald Wood², Joe Chakkalakal³, Christopher T. Ritchlin⁴, Edward Schwarz⁵ and Homaira Rahimi⁶, ¹Pathology, University of Rochester, Rochester, NY, ²University of Rochester, Rochester, NY, ³Orthopaedics, University of Rochester, Rochester, NY, ⁴Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁵Orthopedeatrics, University of Rochester, Rochester, NY, ⁶Rheumatology, University of Rochester/Golisano Children's Hosp, Rochester, NY
Background/Purpose: Rheumatoid arthritis (RA) is a chronic debilitating condition with a 2-3 fold greater prevalence in women than men. Additionally, women have worse disease outcomes…
Abstract Number: 2213 • 2013 ACR/ARHP Annual Meeting
Anti-IL-6 Receptor Antibody Normalizes Both DKK-1 and Sclerostin As Wnt Inhibitors In a Mouse Model Of Collagen-Induced Arthritis
Hiroto Yoshida¹, Mika Yagoto¹, Miho Suzuki¹, Keisuke Tanaka¹, Isao Matsumoto², Takayuki Sumida³ and Yoshihiro Matsumoto¹, ¹Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, ²Department of Internal Medicine, Faculty of Medicine,, University of Tsukuba, Tsukuba, Japan, ³Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
Background/Purpose: The Wnt pathway plays an important role in bone formation and regeneration. This pathway is regulated by several soluble inhibitors such as Dickkopf-1 (DKK-1)…
Abstract Number: 2224 • 2013 ACR/ARHP Annual Meeting
Tumor Necrosis Factor Alpha Induces Anti-Citrullinated Protein Antibodies and Arthritis In Part Through Peptidyl Arginine Deiminase 4
Miriam A. Shelef¹, Jeremy Sokolove², Catriona Wagner³, Eric Sackmann⁴, Thomas Warner⁵, David Beebe⁴, William H. Robinson⁶ and Anna Huttenlocher⁷, ¹Medicine, Univ of Wisconsin Schl of Med, Madison, WI, ²VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, ³VA Palo Alto Heatlh Care System and Stanford University, Palo Alto, CA, ⁴Materials Science Program and Department of Biomedical Engineering, University of Wisconsin, Madison, WI, ⁵Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, WI, ⁶VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ⁷Dept of Pediatrics and MMI, Univ of Wisconsin Schl of Med, Madison, WI
Background/Purpose: Rheumatoid arthritis is an autoimmune, destructive arthritis characterized by anti-citrullinated protein antibodies (ACPAs) and high levels of inflammatory cytokines like tumor necrosis factor alpha…
Abstract Number: 948 • 2013 ACR/ARHP Annual Meeting
Dual Neutralization Of TNF and IL-17 Provides Greater Efficacy In Collagen Induced Arthritis Through Regulation Of a Gene Transcription Program That Includes CXCL1 and CXCL5
Carolyn Cuff¹, Chung-Ming Hsieh², Suzanne Mathieu³, Anwar Murtaza⁴, Margaret Hugunin³, Shaughn Bryant³, Robert O'brien³, Lisa Olson⁵ and Jeffrey Voss³, ¹Immunology, AbbVie, Inc, Worcester, MA, ²Biologics, AbbVie Pharmaceuticals, Worcester, MA, ³Immunology, AbbVie Pharmaceuticals, Worcester, MA, ⁴Broad Institute, Cambridge, MA, ⁵AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA
Background/Purpose: Dual neutralization of TNF and IL-17 is hypothesized to provide greater efficacy in rheumatoid arthritis (RA) and inflammatory diseases compared to either monotherapy as…
Abstract Number: 2079 • 2012 ACR/ARHP Annual Meeting
Anti-Interleukin-6 Receptor Antibody Improves Systemic Osteoporosis in a Mice Model of Glucose-6-Phosphate Isomerase-Induced Arthritis
Hiroto Yoshida¹, Miho Suzuki¹, Misato Hashizume¹, Keisuke Tanaka², Masashi Shiina², Isao Matsumoto³, Takayuki Sumida³ and Yoshihiro Matsumoto², ¹Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, ²Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan, ³Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba City, Japan
Background/Purpose: Patients with rheumatoid arthritis (RA) have a high risk of osteoporosis and osteoporotic fracture. In addition to the primary risk factors for osteoporosis, osteoporosis…
Abstract Number: 1947 • 2012 ACR/ARHP Annual Meeting
Muscle Wasting in HTNFtg Mice, an Animal Model for Rheumatoid Arthritis, Due to Increased Cathepsin L and LC3B Expression
Martin Willburger¹, Birgit Niederreiter¹, Ewald Unger², Josef S. Smolen³, Kurt Redlich¹ and Silvia Hayer¹, ¹Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Center for Medical Physics and Biomedicla Engineering, Medical University of Vienna, Vienna, Austria, ³Division of Rheumatology, Department of Internal Medicine III,, Medical University of Vienna and Hietzing Hospital, Vienna, Austria
Background/Purpose: To investigate the impact of systemic inflammation on skeletal muscles in human tumor necrosis factor transgenic (hTNFtg) animals. Methods: We isolated triceps surae, quadriceps,…
Abstract Number: 346 • 2012 ACR/ARHP Annual Meeting
Sclerostin Protects Against Inflammatory Bone Loss by Regulating Tnfalpha Mediated p38-Mapkinase Activation
Corinna Wehmeyer¹, Christina Wunrau¹, Athanasios Stratis¹, Ina Kramer², Michaela Kneissel², Thomas Pap³ and Berno Dankbar¹, ¹Institute of Experimental Musculoskeletal Medicine (IEMM), University Hospital Muenster, Muenster, Germany, ²Novartis Institutes for Biomedical Research, CH-4056 Basel, Switzerland, ³Institute of Experimental Musculoskeletal Medicine, University Hospital Muenster, Muenster, Germany
Background/Purpose: Progressive loss of joint structure is a hallmark of rheumatoid arthritis (RA). TNFα has been shown to promote the destruction of bone by increasing…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].